Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis

Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis

Related Keywords

Switzerland ,United States ,Munich ,Bayern ,Germany ,Montreal ,Quebec ,Canada ,Rheinfelden ,Aargau ,America ,Swiss ,Chantal Miklosi ,Niclas Berg ,Tillotts Pharma ,Anne Hennecke ,Eli Lilly ,Laurie Doyle ,Vivan Shaw ,Johannes Spleiss ,Life Science Innovation Ii Fund ,Aurka Pharma Inc ,Acanthas Pharma Inc ,Mc Services ,Head Of Scientific Affairs At Tillotts ,Corporate Communications ,Japanese Zeria Group ,Company Lilly ,Mage Biologics Inc ,Mage Biologics ,Science Innovation ,Life Science ,Mage Bio ,Sascha Berger ,General Partner ,Utilizing Tillott ,Board Director ,Scientific Affairs ,North America ,Project Focused Company ,Aurka Pharma ,Acanthas Pharma ,Lead Corporate ,